Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06057038 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | active not recruiting | Phase 1 | 8 | GenmabINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) |
| recruiting |
| Phase 1 / Phase 2 |
| 270 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 12 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT06826313 | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07231211 | A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 258 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07356453 | A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 40 | FoRx Therapeutics AGINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | recruiting | Phase 1 | 103 | GenmabINDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 39 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01480154 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01552356 | Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors | active not recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04565665 | Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia | active not recruiting | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06150885 | A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors(CAR001) | recruiting | Phase 1 / Phase 2 | 60 | Ever Supreme Bio Technology Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | active not recruiting | Phase 1 | 60 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06578624 | Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Lamassu Bio IncINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 392 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | BioNTech SEINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors(TITER) | recruiting | Phase 1 | 77 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 121 | GenmabINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | recruiting | Phase 1 / Phase 2 | 151 | TakedaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07695831 | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors | recruiting | Phase 1 | 112 | GenmabINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07703163 | Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer(SGLT2SOLID) | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811037 | A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 332 | Beijing Sungen Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03006172 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | active not recruiting | Phase 1 | 200 | Genentech, Inc.INDUSTRY | 5 | Sep 8, 2026 | clinicaltrials |
| NCT03875287 | Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | active not recruiting | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | recruiting | Phase 1 / Phase 2 | 225 | Tango Therapeutics, Inc.INDUSTRY | 3 | Sep 8, 2026 | clinicaltrials |
| NCT06561685 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 340 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06694480 | Study of FID-022 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 24 | Fulgent Pharma LLC.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07408258 | Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors | recruiting | Phase 1 | 20 | OncoC4, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07446855 | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours(PARTHENON) | recruiting | Phase 1 / Phase 2 | 180 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT07703878 | A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors | recruiting | Phase 1 | 302 | Gilead SciencesINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07750132 | Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 72 | Beijing StarMab Biomed Technology LtdINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806175 | A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 486 | Rongchang Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04243499 | First-in-Human Study of ICT01 in Patients With Advanced Cancer(EVICTION) | active not recruiting | Phase 1 / Phase 2 | 293 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05315700 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | recruiting | Phase 1 / Phase 2 | 350 | ORIC PharmaceuticalsINDUSTRY | 10 | Sep 4, 2026 | clinicaltrials |
| NCT05372614 | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05688605 | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 18 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06014502 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | recruiting | Phase 1 | 105 | ImmunoGenesisINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06364410 | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors | recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06499350 | A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 33 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06644755 | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Daiichi SankyoINDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Cogent Biosciences, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials